Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Sarcoma 2 Small Cell Lung Carcinoma 1 Recurrence 1 Prostatic Neoplasms 1 Leiomyosarcoma 1 Ichthyosis, X-Linked 1 Glioblastoma 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Temozolomide 40 Magnetic Resonance Spectroscopy 19 Radiotherapy 18 Specimen Handling 14 Radiation 12 Bevacizumab 11 Lomustine 9 pembrolizumab 6 fludarabine 5 Surgical Procedures, Operative 5 atezolizumab 4 Nivolumab 4 Ipilimumab 4 Cyclophosphamide 4 Carboplatin 4 Biopsy 4 cemiplimab 3 azeliragon 3 Immunoglobulin G 3 Disulfides 3 Aminolevulinic Acid 3 veliparib 2 trametinib 2 rocakinogene sifuplasmid 2 poly ICLC 2 olaparib 2 lutetium Lu 177 dotatate 2 durvalumab 2 dabrafenib 2 contrast agent BR1 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Glioblastoma × ADI PEG20 × 90 days × Clear all

NCT03970447 2026-06-03

GBM AGILE

Global Coalition for Adaptive Research

Phase 2/3 Recruiting

Glioblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡